## 2 Results and Discussion
\begin{table}
\begin{tabular}{c c c c c} \hline \multirow{2}{*}{**Compound**} & \multicolumn{4}{c}{**Minimum Inhibitory Concentration (\(\mu\)g/mL)**} \\ \cline{2-5}  & & _Enterococcus durans_ & _Bacillus subtilis_ & _Escherichia coli_ \\ \hline
1 & & 31.2 & \(>\)1000 & \(>\)1000 \\
5 & & 250 & 250 & 250 \\
6 & & 3.1 & 62.5 & 12.5 \\
7 & & 310 & 310 & \(>\)1000 \\
8 & & 3.1 & 3.1 & 62.5 \\
9 & & & & \\ \end{tabular}
\end{table} 
Table 1: The evaluation of antibacterial activity of compounds **1**, **5**–**14**. As can be seen from the presented data (Table 1), compound **1** is active against _Enterococcusurans_, but has low activity against other microorganisms. Compounds **5** and **6** differ only by one group, CH\({}_{2}\), but the activity of these compounds varies considerably. Compound **5** with a shorter carbon chain shows low activity, while compound **6** is superior to antibiotic gentamicin against both the Gram-positive _Enterococcusurans_ and the Gram-negative _Escherichia coli_ (Table 1). The obtained results were compared with the activity of standard aminoglycos antibiotic gentamicin, the minimal inhibitory concentrations of which are 25, 50 and 100 ug/mL against _Enterococcusurans_, _Bacillus subtilis_ and _Escherichia coli_, respectively. Having the same molecular formula, products **7** and **8** are isomeric compounds obtained by the reactions of sulfenyl chloride **3** with isoeugenol and eugenol, respectively. These compounds differ significantly (by about 10 times) in activity (Table 1). The eugenol-derived product **8**, as well as that obtained from methyl eugenol, compound **10**, are highly active against bacteria _Enterococcusurans_ and _Bacillus subtilis_ and are superior in their activity compared the antibiotic gentamicin against these microorganisms. The structurally related compounds **7** and **9** (obtained from methyl isoeugenol and _trans_-anethole), which formally differ in one hydroxyl group, show activity against Gram-positive bacteria _Enterococcusurans_ and _Bacillus subtilis_, but are inferior to gentamicin (Table 1). Comparison of the structurally related compounds **11**, **13** and **14** reveals the higher activity of products **11** and **13** (obtained from styrene and 4-methylstyrene), which are superior to the activity of gentamicin against bacteria _Enterococcusurans_. \(\alpha\)-methylstyrene-derived product **14** shows lower activity (Table 1). The highest level of activity was shown by product **12** (obtained from 1\(H\)-indene), which significantly exceeds the activity of gentamicin and all the obtained compounds \begin{table}
\begin{tabular}{c c c c} \hline \hline \multirow{2}{*}{**Compound**} & \multicolumn{3}{c}{**Minimum Inhibitory Concentration (ug/mL)**} \\ \cline{2-4}  & _Enterococcusurans_ & _Bacillus subtilis_ & _Escherichia coli_ \\ \hline
9 & 250 & 125 & \(>\)1000 \\
10 & 3.1 & 25 & 1000 \\
11 & 6.2 & 250 & 125 \\
12 & 5.0 & 0.6 & 3.1 & 250 \\
13 & 6.2 & 125 & 250 \\
14 & 62.5 & 250 & 125 \\
12 & 25 & 50 & 100 \\ \hline \hline \end{tabular}
\end{table} 
Table 1: _Cont._against the bacteria _Enterococcusurans_ and is more than 15 times higher than the activity of this antibiotic against _Bacillus subtilis_. The structural assignments of synthesized compounds were made using \({}^{1}\)H- and \({}^{13}\)C-NMR spectroscopy including _J_-modulation \({}^{13}\)C-NMR experiments and confirmed by elemental analysis (see more in Supplementary Materials). The groups SCH-CH\({}_{2}\)N\({}^{+}\), SCH\({}_{2}\)-CHN\({}^{+}\) and SCH-CHN\({}^{+}\) provide characteristic signals in the \({}^{1}\)H- and \({}^{13}\)C-NMR spectra. Thus, the carbon atoms of these groups, bonded with one or two protons, reveal characteristic signals in the \({}^{13}\)C-NMR spectra. For example, the CH\({}_{2}\)N\({}^{+}\) group manifests itself at -62 ppm, while signals of the CHN\({}^{+}\) moiety are observed in the lowfield region of -69-75 ppm in the \({}^{13}\)C-NMR spectra of the obtained compounds.